This research study is studying a drug as a possible treatment for BPDCN.
The intervention involved in this study is: Venetoclax
This research study is a Phase I clinical trial, which tests the safety of an investigational
drug and also tries to define the safest dose of the investigational drug to use for further
studies. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved venetoclax for this specific
disease but it has been approved for other uses.
Based on laboratory data where it was found that BPDCN cells die after treatment with
Venetoclax, the investigators believe that this drug will be effective in treating patients
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.